Core Viewpoint - Haofan Bio reported a significant increase in revenue for Q3 2025, but a decline in net profit compared to the previous year [1] Financial Performance - In Q3 2025, the company achieved a revenue of 164 million yuan, representing a year-on-year growth of 59.45% [1] - The net profit attributable to shareholders was 23.35 million yuan, showing a decrease of 23.50% year-on-year [1] - Basic earnings per share for Q3 2025 were 0.22 yuan [1] Year-to-Date Performance - For the first three quarters of 2025, the company reported a total revenue of 435 million yuan, which is a year-on-year increase of 32.47% [1] - The net profit attributable to shareholders for the first three quarters was 99.24 million yuan, reflecting a growth of 3.01% year-on-year [1] - Basic earnings per share for the first three quarters were 0.93 yuan [1]
昊帆生物：第三季度归母净利润2335.35万元，同比下降23.50%